Geron Corporation is a clinical biopharmaceutical company which centers on developing and commercializing treatments for myeloid hematologic malignancies. Their current focus is on Imetelstat, a telomerase inhibitor in Phase 3 clinical trials that helps curb malignant stem and progenitor cell proliferation in hematologic myeloid malignancies, primarily for myelodysplastic syndromes and myelofibrosis. The company was founded in 1990 and has its headquarters located in Foster City, California.